Nuwellis expands Aquadex strategy into broader extracorporeal therapy platform
NUWE•Nuwellis expands Aquadex strategy
Nuwellis launched a development program to expand its Aquadex SmartFlow into a broader extracorporeal therapy platform for critical care.
Work targets higher blood-flow rates, wider operating pressure ranges, and broader compatibility with advanced extracorporeal therapies.
The strategy aims to expand the long-term market beyond fluid overload into blood purification, immunomodulation, and extracorporeal life support.
The platform could support collaborations with developers of blood purification therapies using Nuwellis’ precise fluid-management technology.
The initiative remains at the research stage and is not FDA cleared or available for commercial sale or clinical use.
